Announcements and demos at AGBT signaled intensifying competition at the high end of sequencing: Element Biosciences, Ultima Genomics, Roche (Axelios nanopore), and Complete Genomics all showcased or priced instruments that compress per‑genome costs below Illumina’s incumbent NovaSeq economics. Illumina responded with a NovaSeq X roadmap promising higher accuracy and 40% flow‑cell output gains. Speakers at the meeting told attendees that multiple suppliers now claim sub‑$200—or even sub‑$150—human genome costs, a potential inflection point for clinical high‑throughput use cases like minimal residual disease testing. Analysts and core labs flagged supply and run‑flexibility questions even as capacity projections expand. The technology push could reshape clinical sequencing economics, core‑lab purchasing decisions, and the landscape for population genomics and diagnostic scale‑up.